Equillium Inc

NASDAQ:EQ

1.61

-0.12 (-6.94%)

4:35:33 PM EDT: $1.66 +0.05 (+3.11%)

Market Cap (Intraday)	52.82M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$5.73 Million
Adjusted EPS	-$0.17

See more estimates

10-Day MA	$1.84
50-Day MA	$2.26
200-Day MA	$1.11

See more pivots

Equillium Inc Stock, NASDAQ:EQ

2223 Avenida de la Playa, Suite 105, La Jolla, California 92037

United States of America

Phone: +1.858.240.1200

Number of Employees: 44

http://www.equilliumbio.com

Description

Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly in March, 2017 and is headquartered in La Jolla, CA.